2025-06-10-Jefferies-泰莎基因疗法（TSHA）_在IRSF与管理层的跟进；海报会议上研究人员的点滴信息_8页_128kb

Summary of Taysha Gene Therapies (TSHA) Equity Research Report

Date: June 10, 2025
Rating: BUY
Price Target: $8.00 (+186% upside from current price)
Market Cap: $754.1M

Key Highlights

• FLASH NOTE: Jefferies maintains a BUY rating with elevated upside potential based on the maturing Rett syndrome gene therapy dataset discussed at IRSF 2025. Key updates from management and KOLs emphasize strong pivotal trial progress, regulatory alignment, and competitive positioning.
• Company Overview: Taysha Gene Therapies develops AAV-based gene therapies for monogenic CNS diseases. Its lead asset, TSHA-102, is in Phase 3 for Rett syndrome, showing high response rates and neurological improvements in clinical settings.
• Recent Developments: Management updated investors at IRSF 2025, confirming key pivotal trial details, including a 15-patient cohort design consistent with FDA recommendations. The trial protocol amendment is expected in Q2 2025, with enrollment starting in Q4 2025–Q1 2026.
• Clinical Data: High-dose arm showed 100% response rates (75–83% at 6 months) and significant milestone gains, such as improved frontal cortex function and speech, supporting a positive pivotal trial outcome. DGTT DG responded with high confidence in the data, indicating widespread biodistribution via intrathecal delivery.
• Competition: Competitor NGNE is advancing its own gene therapy but faces limitations in study size and data calibration for key milestones like CGI-I. TSHA emphasized its trial design may offer faster approval pathways via FDA discussions on interim analyses.
• Analyst Views: Overall sentiment is "enthusiastic," with management highlighting a clear path to commercial readiness and safety enhancements for younger patient cohorts. KOL feedback confirmed the treatment's effects but noted the need for standardized metrics in the field.
• Valuation and Risks: Jefferies assigns a $8.00 price target justified by DCF and probability-adjusted EPS models. Risks include efficacy, toxicity, competition, and potential delays in trial timelines; however, the high statistical confidence in trial outcomes mitigates these concerns.
• Next Events: Key dates include the opt-in data submission mid-2025, pending FDA review, and potential interim updates as early as summer 2025.

Conclusion: TSHA is recognized for its robust ongoing trial design, significant positive clinical data, and strong regulatory alignment, with high probability of approval and commercial success based on current trends.